Low-dose naltrexone for treatment of dermatologic conditions: a clinical review.
Review
Overview
abstract
Naltrexone is a long-acting opioid receptor antagonist that may be compounded at lower doses (1-5mg) to treat inflammatory or autoimmune conditions. Low-dose naltrexone (LDN) transiently blocks the opioid receptor, resulting in increased ligand and receptor expression, favoring κ over μ receptors and decreasing inflammatory mediators and itch. In addition, LDN antagonizes non-opioid receptors including the pro-inflammatory Toll-like receptor 4 (TLR-4). Altogether, the anti-inflammatory properties of LDN have supported its use in dermatologic conditions, including Hailey-Hailey disease, Darier disease, pruritus, lichen planus, psoriasis, dermatomyositis, hidradenitis suppurativa, and body-focused repetition behaviors. LDN has demonstrated efficacy in treating these dermatologic conditions with improvement in disease severity, body surface area involvement, and associated symptoms. However, clinical response may vary based on initial disease presentation. There is also evidence supporting LDN in combination with other anti-inflammatory agents. Fewer side effects have been reported with LDN compared to standard naltrexone doses, though larger studies are required to optimize dosage and management. LDN is commonly compounded by a pharmacy which may pose barriers to access. In this clinical review, we describe updated and practical uses of LDN in inflammatory dermatologic conditions, associated side effects, cost barriers, and comparisons to standard naltrexone doses.
